Background The humoral immune response after primary immunisation with a SARS-CoV-2
vector vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an …

Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
have been developed and administered to mitigate the coronavirus disease 2019 (COVID …

The humoral immunity after SARS-CoV-2 infection or vaccination was examined.
Convalescent sera after infection with variants of concern (VOCs: B. 1.1. 7, n= 10; B. 1.351 …

To evaluate vaccine-induced humoral and cell-mediated immunity at 6 months after
completion of two doses of BNT162b2 vaccination, immunoglobulin G against SARS-CoV-2 …

Background Mass vaccination is the key element in controlling current COVID-19 pandemic.
Studies comparing immunogenicity of different COVID-19 vaccines are largely lacking. We …

Antibody responses to SARS-CoV-2 vaccines vary for reasons that remain poorly
understood. A range of sociodemographic, behavioural, clinical, pharmacologic and …

While the immunogenicity of inactivated vaccines against coronavirus disease 2019 (COVID‐
19) has been characterized in several well-conducted clinical trials, real-world evidence …

Objectives First, to describe SARS-CoV-2 T cell and antibody responses in a prospective
cohort of healthcare workers that suffered from mild to moderate COVID-19 approximately …

The humoral and cellular immune responses against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) upon the coronavirus disease 2019 (COVID-19) vaccination …

To date there has been limited head-to-head evaluation of immune responses to different
types of COVID-19 vaccines. A real-world population-based longitudinal study was …